Drug intelligence / Profile preview

CD371-SAVVY-IL18

Development stage: Unknown
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

CD371-SAVVY-IL18 is an investigational, autologous chimeric antigen receptor (CAR) T cell therapy targeting CD371, engineered with a SAVVY (YSNVZ) chimeric antigen receptor and armored to constitutively secrete interleukin-18 (IL-18). This therapy is being developed for relapsed or refractory acute myeloid leukemia (AML). The CAR enables the T cells to identify and kill CD371-expressing leukemia cells, while the IL-18 secretion is designed to enhance antitumor immune responses within the tumor microenvironment. The therapy is currently being evaluated in a phase 1 clinical trial for safety, expansion, cytokine secretion, and preliminary effectiveness in AML patients.

Other names: CD371-SAVVYz-IL18 CAR T-cellsCD-371-SAVVYz-IL18 CAR T-cellsCD 371-SAVVYz-IL18 CAR T-cellsCD371-YSNVZ-IL18 CAR T cellsCD-371-YSNVZ-IL18 CAR T cellsCD 371-YSNVZ-IL18 CAR T cells

Targets

CLEC12AIL-18R (Interleukin-18 receptor complex)

Beyond the preview

Go deeper on CD371-SAVVY-IL18.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CD371-SAVVY-IL18.

Explore the full profile